FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997386670> ?p ?o ?g. }

• W1997386670 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackgroundFor almost two decades tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) has been under extensive development as a potential therapeutic agent. TRAIL/Apo2L is a member of the TNF superfamily with unique ability to induce apoptosis in cancer cells while remaining neutral to normal cells.Tumor growth is tightly related to new blood vessel formation and tissue remodeling. Platelet derived growth factor (PDGF) is important in vascular physiological and pathological development. Inhibition of PDGF pathway blocks angiogenesis what results in reduction of tumor growth.We proposed a novel fusion protein (AD-O54.9) with dualistic proapoptotic and antiangiogenic activity. Our molecule consists of the soluble recombinant TRAIL/Apo2L variant linked with an effector peptide sequence and an activation motif recognized by tumor-specific proteases (MMPs, uPa) between. The effector peptide is composed of 19-amino acid fragment derived from human PDGF, which binds the PDGF receptors competitively to the natural ligand while being itself devoid of activity. As a consequence, angiogenic activity of PDGF is blocked, stimulation of new blood vessels formation does not occur and finally tumor growth is inhibited.Materials and methodsAD-O54.9 protein was expressed in E. coli, using pET expression system, and purified by IEC chromatography. Cytotoxic activity of AD-O54.9 was examined using a propidium iodide assay and its antiangiogenic activity was evaluated by HUVEC tube formation and ring aortic assays. Safety was tested on human primary hepatocytes. The proapoptotic and antiproliferative activity was tested using molecular biology and flow cytometry methods. In vivo potential was examined on mice xenograft models of human colorectal adenocarcinoma (Colo205), human lung carcinoma (NCI-H460-luc2), human pancreatic carcinoma (MIA PaCa-2) and human oesophageal adenocarcinoma (OE19) cell lines where molecules showed anticancer activity.ResultsThe molecule showed in vitro specific cytotoxic effect on various primary cancer cell lines at IC50 below 0.01 ng/ml. We demonstrated that AD-O54.9 is a very potent apoptosis inducer and inhibitor of angiogenesis. This fusion protein showed superior efficacy displaying significant tumor volume regression compared with TRAIL/Apo2L and standard chemotherapeutic agents.ConclusionsThe obtained results confirm that we developed a very promising fusion molecule with a high potential of anticancer activity that could be considered as a novel therapeutic agent.Citation Format: Piotr Rozga, Jerzy Pieczykolan, Bartlomiej Zerek, Anna Pieczykolan, Marlena Galązka, Katarzyna Bukato, Michal Szymanik, Albert Jaworski, Sebastian Pawlak, Malgorzata Teska-Kaminska, Anna Grochot-Przeczek. Induction of apoptosis and inhibition of angiogenesis by novel fusion protein - AD-O54.9 as a new preclinical strategy in cancer treatment. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2276. doi:10.1158/1538-7445.AM2014-2276" @default.
• W1997386670 created "2016-06-24" @default.
• W1997386670 creator A5013520147 @default.
• W1997386670 creator A5018248527 @default.
• W1997386670 creator A5018257810 @default.
• W1997386670 creator A5040898250 @default.
• W1997386670 creator A5043992991 @default.
• W1997386670 creator A5050707815 @default.
• W1997386670 creator A5057660348 @default.
• W1997386670 creator A5065229144 @default.
• W1997386670 creator A5071091408 @default.
• W1997386670 creator A5079043540 @default.
• W1997386670 creator A5079868681 @default.
• W1997386670 date "2014-09-30" @default.
• W1997386670 modified "2023-10-16" @default.
• W1997386670 title "Abstract 2276: Induction of apoptosis and inhibition of angiogenesis by novel fusion protein - AD-O54.9 as a new preclinical strategy in cancer treatment" @default.
• W1997386670 doi "https://doi.org/10.1158/1538-7445.am2014-2276" @default.
• W1997386670 hasPublicationYear "2014" @default.
• W1997386670 type Work @default.
• W1997386670 sameAs 1997386670 @default.
• W1997386670 citedByCount "0" @default.
• W1997386670 crossrefType "proceedings-article" @default.
• W1997386670 hasAuthorship W1997386670A5013520147 @default.
• W1997386670 hasAuthorship W1997386670A5018248527 @default.
• W1997386670 hasAuthorship W1997386670A5018257810 @default.
• W1997386670 hasAuthorship W1997386670A5040898250 @default.
• W1997386670 hasAuthorship W1997386670A5043992991 @default.
• W1997386670 hasAuthorship W1997386670A5050707815 @default.
• W1997386670 hasAuthorship W1997386670A5057660348 @default.
• W1997386670 hasAuthorship W1997386670A5065229144 @default.
• W1997386670 hasAuthorship W1997386670A5071091408 @default.
• W1997386670 hasAuthorship W1997386670A5079043540 @default.
• W1997386670 hasAuthorship W1997386670A5079868681 @default.
• W1997386670 hasConcept C104317684 @default.
• W1997386670 hasConcept C123894998 @default.
• W1997386670 hasConcept C153911025 @default.
• W1997386670 hasConcept C170493617 @default.
• W1997386670 hasConcept C17991360 @default.
• W1997386670 hasConcept C185592680 @default.
• W1997386670 hasConcept C190283241 @default.
• W1997386670 hasConcept C203014093 @default.
• W1997386670 hasConcept C2775934118 @default.
• W1997386670 hasConcept C2775960820 @default.
• W1997386670 hasConcept C2780394083 @default.
• W1997386670 hasConcept C31573885 @default.
• W1997386670 hasConcept C40767141 @default.
• W1997386670 hasConcept C502942594 @default.
• W1997386670 hasConcept C51785407 @default.
• W1997386670 hasConcept C55493867 @default.
• W1997386670 hasConcept C86803240 @default.
• W1997386670 hasConcept C95444343 @default.
• W1997386670 hasConceptScore W1997386670C104317684 @default.
• W1997386670 hasConceptScore W1997386670C123894998 @default.
• W1997386670 hasConceptScore W1997386670C153911025 @default.
• W1997386670 hasConceptScore W1997386670C170493617 @default.
• W1997386670 hasConceptScore W1997386670C17991360 @default.
• W1997386670 hasConceptScore W1997386670C185592680 @default.
• W1997386670 hasConceptScore W1997386670C190283241 @default.
• W1997386670 hasConceptScore W1997386670C203014093 @default.
• W1997386670 hasConceptScore W1997386670C2775934118 @default.
• W1997386670 hasConceptScore W1997386670C2775960820 @default.
• W1997386670 hasConceptScore W1997386670C2780394083 @default.
• W1997386670 hasConceptScore W1997386670C31573885 @default.
• W1997386670 hasConceptScore W1997386670C40767141 @default.
• W1997386670 hasConceptScore W1997386670C502942594 @default.
• W1997386670 hasConceptScore W1997386670C51785407 @default.
• W1997386670 hasConceptScore W1997386670C55493867 @default.
• W1997386670 hasConceptScore W1997386670C86803240 @default.
• W1997386670 hasConceptScore W1997386670C95444343 @default.
• W1997386670 hasLocation W19973866701 @default.
• W1997386670 hasOpenAccess W1997386670 @default.
• W1997386670 hasPrimaryLocation W19973866701 @default.
• W1997386670 hasRelatedWork W1966313456 @default.
• W1997386670 hasRelatedWork W1993397531 @default.
• W1997386670 hasRelatedWork W1998008191 @default.
• W1997386670 hasRelatedWork W2004548573 @default.
• W1997386670 hasRelatedWork W2020274305 @default.
• W1997386670 hasRelatedWork W2023463042 @default.
• W1997386670 hasRelatedWork W2028324191 @default.
• W1997386670 hasRelatedWork W2054550762 @default.
• W1997386670 hasRelatedWork W2062739811 @default.
• W1997386670 hasRelatedWork W2122760343 @default.
• W1997386670 hasRelatedWork W2124186983 @default.
• W1997386670 hasRelatedWork W2125970611 @default.
• W1997386670 hasRelatedWork W2128380044 @default.
• W1997386670 hasRelatedWork W2152203644 @default.
• W1997386670 hasRelatedWork W2471142276 @default.
• W1997386670 hasRelatedWork W2561162390 @default.
• W1997386670 hasRelatedWork W2579249397 @default.
• W1997386670 hasRelatedWork W3041976739 @default.
• W1997386670 hasRelatedWork W2104745741 @default.
• W1997386670 hasRelatedWork W2593499881 @default.
• W1997386670 isParatext "false" @default.
• W1997386670 isRetracted "false" @default.
• W1997386670 magId "1997386670" @default.
• W1997386670 workType "article" @default.